Himmelfarb Health Sciences Library, The George Washington University

Health Sciences Research Commons
Biochemistry and Molecular Medicine Faculty
Publications

Biochemistry and Molecular Medicine

8-17-2012

Small-molecule inhibition of BRDT for male
contraception.
Martin M. Matzuk
Baylor College of Medicine

Michael R. McKeown
Dana-Farber Cancer Institute, Boston, MA

Panagis Filippakopoulos
University of Oxford, Oxford, UK

Qinglei Li
College of Veterinary Medicine and Biomedical Sciences, Texas A&M, Houston, TX

Lang Ma
Baylor College of Medicine
See next page for additional authors

Follow this and additional works at: http://hsrc.himmelfarb.gwu.edu/smhs_biochem_facpubs
Part of the Biochemistry, Biophysics, and Structural Biology Commons
Recommended Citation
Matzuk, M. M., McKeown, M. R., Filippakopoulos, P., Li, Q., Ma, L., Agno, J. E., . . . Bradner, J. E. (2012). Small-molecule inhibition of
BRDT for male contraception. Cell, 150(4), 673-684.

This Journal Article is brought to you for free and open access by the Biochemistry and Molecular Medicine at Health Sciences Research Commons. It
has been accepted for inclusion in Biochemistry and Molecular Medicine Faculty Publications by an authorized administrator of Health Sciences
Research Commons. For more information, please contact hsrc@gwu.edu.

Authors

Martin M. Matzuk, Michael R. McKeown, Panagis Filippakopoulos, Qinglei Li, Lang Ma, Julio E. Agno,
Madeline E. Lemieux, Sarah Picaud, Richard M. Yu, Jun Qi, Stefan Knapp, and James E. Bradner

This journal article is available at Health Sciences Research Commons: http://hsrc.himmelfarb.gwu.edu/smhs_biochem_facpubs/70

Small-Molecule Inhibition
of BRDT for Male Contraception
Martin M. Matzuk,1,2,3,4,5,6,* Michael R. McKeown,7 Panagis Filippakopoulos,8 Qinglei Li,9 Lang Ma,1 Julio E. Agno,1
Madeleine E. Lemieux,7,10 Sarah Picaud,8 Richard N. Yu,11 Jun Qi,7 Stefan Knapp,8,12 and James E. Bradner7,13,*
1Department

of Pathology & Immunology
of Molecular and Cellular Biology
3Department of Molecular and Human Genetics
4Department of Pharmacology
5Center for Drug Discovery
6Center for Reproductive Medicine
Baylor College of Medicine, Houston, TX 77030, USA
7Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
8Nuffield Department of Clinical Medicine, Structural Genomics Consortium, University of Oxford, Oxford OX3 7DQ, UK
9Department of Veterinary Integrative Biosciences, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University,
College Station, TX 77843, USA
10Bioinfo, Ottawa, Ontario K1J 8G4, Canada
11Department of Urology, Children’s Hospital Boston, Boston, MA 02115, USA
12Department of Biochemistry and Molecular Biology, George Washington University, School of Medicine and Health Sciences, Washington,
DC 20037, USA
13Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
*Correspondence: mmatzuk@bcm.edu (M.M.M.), james_bradner@dfci.harvard.edu (J.E.B.)
http://dx.doi.org/10.1016/j.cell.2012.06.045
2Department

Open access under CC BY license.

SUMMARY

A pharmacologic approach to male contraception
remains a longstanding challenge in medicine.
Toward this objective, we explored the spermatogenic effects of a selective small-molecule inhibitor
(JQ1) of the bromodomain and extraterminal (BET)
subfamily of epigenetic reader proteins. Here, we
report potent inhibition of the testis-specific member
BRDT, which is essential for chromatin remodeling
during spermatogenesis. Biochemical and crystallographic studies confirm that occupancy of the BRDT
acetyl-lysine binding pocket by JQ1 prevents recognition of acetylated histone H4. Treatment of mice
with JQ1 reduced seminiferous tubule area, testis
size, and spermatozoa number and motility without
affecting hormone levels. Although JQ1-treated
males mate normally, inhibitory effects of JQ1 evident
at the spermatocyte and round spermatid stages
cause a complete and reversible contraceptive
effect. These data establish a new contraceptive
that can cross the blood:testis boundary and inhibit
bromodomain activity during spermatogenesis, providing a lead compound targeting the male germ
cell for contraception.
INTRODUCTION
Although 4% of the mammalian genome encodes genes
expressed in male germ cells during spermatogenesis (Schultz

et al., 2003), contraceptive drugs for men have remained elusive.
To date, the only drugs in clinical trials are testosterone analogs
that alter endogenous androgen production, although there is
a short list of other possible targets (e.g., GAPDHS) and drugs
(e.g., gamendazole) (Aitken et al., 2008). This lack of contraceptive alternatives for men is partially responsible for the high rate
of unplanned pregnancies, especially in teenagers, and contributes to the maternal mortality, ethical, social, and financial costs
associated with abortions and deliveries to single mothers. To
approach this dearth of contraceptive alternatives for men, we
have undertaken to develop small molecules that could target
spermatogenic-specific proteins that have been shown to be
essential for both spermatogenesis and fertility in mammals.
One such contraceptive target is the testis-specific and bromodomain-containing protein BRDT.
BRDT is a tissue-restricted, chromatin-associated protein expressed in pachytene spermatocytes, diplotene spermatocytes,
and round spermatids (Shang et al., 2007). During postmeiotic
maturation, BRDT localizes to the nucleus and reorganizes
hyperacetylated histones through twin acetyl-lysine recognition
modules, or bromodomains (Berkovits and Wolgemuth, 2011;
Morinière et al., 2009; Shang et al., 2007). The essential role of
BRDT in spermatogenesis is mediated by the first bromodomain
(BRDT(1); Figure 1A), which binds the tetra-acetylated aminoterminal tail of histone 4 (H4Kac4) with moderate potency
(20 mM) (Morinière et al., 2009). Structural studies of murine
BRDT have demonstrated that BRDT(1) binds a diacetylated
histone 4 peptide (H4K5ac8ac) in part through a conserved
asparagine (Morinière et al., 2009), akin to other bromodomain
coactivator proteins (Dhalluin et al., 1999). Genetic studies
of BRDT have demonstrated that selective deletion of the
BRDT(1)-encoding region is sufficient to confer sterility in
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(A) Domain diagram of BRDT. Sequence boundaries for recombinant BRDT(1) are shown in bold.
(B) Structure of the active (+)-JQ1 enantiomer.
(C) Protein alignment reveals high sequence
identity between homologous and orthologous
domains. Identical (pink) and similar (blue) residues are highlighted. Major helical elements are
depicted above the sequence. The conserved
asparagine mediating acetyl-lysine recognition is
depicted with a blue star. Contacts between
(+)-JQ1 and BRDT(1) are depicted with a
black star.
(D) Competitive inhibition of human (squares)
and mouse (circles) BRDT(1) binding to synthetic
biotinylated H4Kac4 by (+)-JQ1 using proximity
detection assays (hBRDT(1) IC50 = 11 nM;
mBrdt(1) IC50 = 10 nM).
(E) ITC data for titration of H4Kac4 into hBRDT(1)
(black line) or into a 1:0.8 molar mixture of
hBRDT(1) and (+)-JQ1 (red line). The inset shows
normalized binding enthalpies corrected for heat
of dilution as a function of binding site saturation.
Solid lines represent a nonlinear least-squares fit
using a single-site binding model.
(F) Equilibrium binding constants and binding
energies of (+)-JQ1 to human and mouse BRDT
bromodomains measured by ITC.
See also Data S1 and S2 and Table S1.
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Figure 1. BRDT Inhibition by the BET Bromodomain Inhibitor JQ1
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We report here that direct inhibition of BRDT by a small-molehomozygous hypomorphic male mice (Shang et al., 2007), and
a recently published genome-wide association study of idio- cule bromodomain inhibitor exerts a dose- and time-dependent
pathic male infertility identified single-nucleotide polymorphisms inhibitory effect on spermatogenesis. Structural studies of
of BRDT as significantly associated with oligozoospermia or BRDT(1) bound to JQ1 reveal ligand-receptor shape compleazoospermia in European men (Aston et al., 2010). These mentarity and complete occlusion of the acetyl-lysine recogniinsights establish a compelling rationale to target BRDT for tion cavity. These and further biochemical studies establish the
a contraceptive effect.
molecular mechanism of potent BRDT inhibition observed in vivo,
Recently, we established the feasibility of targeting human where JQ1 targets meiotic and postmeiotic male germ cells,
bromodomains with acetyl-lysine competitive small molecules leading to impaired spermatogenesis and compromised motility.
(Filippakopoulos et al., 2010). Our index study described a potent In mating studies, JQ1 accomplishes a complete and reversible
thienodiazepine inhibitor ((+)-JQ1; Figure 1B; Kd = 90 nM) of the contraceptive effect in males without adversely affecting
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testosterone levels or mating behaviors and without prompting
obvious teratogenic effects in offspring. These results indicate
that targeting a developmental epigenetic reader protein with
an orally bioavailable small molecule can modulate male fertility
for a contraceptive effect.
RESULTS
Molecular Recognition of BRDT by JQ1
To assess competitive binding to BRDT(1), we devised homogeneous, luminescence proximity assays that are capable of
quantifying binding of a synthetic, biotinylated tetra-acetylated
histone 4 peptide (H4Kac4, residues 1–20) to recombinant
epitope-tagged murine or human BRDT(1). Dose-ranging studies of (+)-JQ1 demonstrated potent inhibition of H4Kac4
binding with a half-maximum inhibitory concentration (IC50)
value of 10 nM for murine BRDT(1) and 11 nM for human
BRDT(1) (Figure 1D). In contrast, the ( )-JQ1 enantiomer
was inactive for either ortholog, establishing stereospecific,
ligand-competitive binding. To confirm competitive inhibition
of the acetyl-lysine binding module, isothermal titration calorimetry (ITC) was performed on human BRDT(1), employing
a synthetic H4Kac4 peptide in the presence and absence of
(+)-JQ1 (Figure 1E). This peptide was found to bind two
protein modules concomitantly with a Kd of 25.5 mM, in good
agreement with published data (Morinière et al., 2009). This
interaction was directly inhibited in the presence of (+)-JQ1
that partially saturated the acetyl-lysine binding (ratio 1:0.8)
due to solubility limits of the inhibitor. The remaining unoccupied sites bound the H4Kac4 peptide with identical affinity
and expected stoichiometry (Table S1). Binding free energies
and dissociation constants (KD) determined by ITC for each
bromodomain of human and murine BRDT confirm potent,
specific (ratio 1:1) interactions with all domains (KD = 44–
190 nM; Figure 1F). Notably, (+)-JQ1 binds murine BRDT(1)
with high ligand efficiency (LE = 0.30), compared to reported inhibitors of protein-protein interactions (Wells and
McClendon, 2007).
The mode of binding of (+)-JQ1 to BRDT(1) was established by
X-ray crystallography at high-resolution (Figure 2 and Table S2).
Similar to the structure of murine BRDT(1) (Morinière et al.,
2009), human BRDT(1) exhibits the canonical structural features
of a bromodomain, namely a left-handed bundle of four antiparallel a helices (aZ, aA, aB, and aC) and a hydrophobic acetyllysine binding pocket defined by interhelical ZA and BC loops
(Figures 2A–2C) (Dhalluin et al., 1999). The observed, extraordinary shape complementarity between (+)-JQ1 and BRDT(1)
explains the increased potency of (+)-JQ1 compared to the
physiologic H4Kac4 ligand. In addition, (+)-JQ1 engages all
surface residues analogous to those on murine BRDT(1) mediating molecular recognition of H4K5ac8ac (Figures 2D and 2E)
(Morinière et al., 2009). Notable examples include a hydrogen
bond linking the triazole ring and the evolutionarily conserved
asparagine (Asn109), as well as extensive hydrophobic contacts
with the ZA and BC loop regions (Figure 2B). These biochemical
and structural studies confirm and explain potent, acetyl-lysine
competitive inhibition of BRDT(1) by (+)-JQ1 (hereafter referred
to as JQ1).

Testis Bioavailability of JQ1
To test the ability of JQ1 to reach its contraceptive target cells,
the testicular bioavailability of JQ1 was assessed by serum
and tissue pharmacokinetic analysis. Following a single intraperitoneal (i.p.) dose of JQ1 (50 mg/kg) in male mice, measurements
of JQ1 concentration were made in serum, testis, and brain (Figure 3A and Table S3). Overall, JQ1 exhibits excellent testicular
bioavailability (AUCtestis/AUCplasma = 259%), suggesting preferential distribution into this tissue compartment with rapid
(Tmax = 0.25 hr) and pronounced exposure (Cmax = 34 mg/ml).
Corroborating barrier permeability by JQ1, nearly uniform
blood-brain barrier permeability was observed after singledose pharmacokinetic studies (AUCbrain/AUCplasma = 98%).
JQ1 Impairs Sperm Count and Motility
To determine the possible consequences of blocking BRDT
function in vivo, we tested the spermatogenic effects of JQ1
administered to male mice. First, juvenile or adult male mice
were administered daily i.p. injections of JQ1 (50 mg/kg once
daily [QD]) or vehicle control over a 3 or 6 week period. After
drug or vehicle treatment, mice were either sacrificed or mated
to females while continuing to receive JQ1. All JQ1-treated
males had a significant reduction in testis volume (Figures 3B
and 3C). With daily injections of 50 mg/kg JQ1, males treated
from 3–6 weeks of age showed a reduction to 75.4% of control,
males treated from 6–9 weeks of age showed a reduction to
54.7%, and males treated for 6 weeks with JQ1 (6–12 weeks
of age) showed a reduction to 40.6% (Figure 3C). Thus, longer
treatment with JQ1 has the most prominent effect on testicular
volume.
To examine the effect on sperm production, sperm counts
were determined after JQ1 or vehicle treatment. Epididymal
sperm number was reduced to 28% of control after 3 weeks of
50 mg/kg daily exposure (3–6 weeks of age) and 11% of control
after 6 weeks of treatment (6–12 weeks of age) (Figure 3D).
Analysis of sperm motility after 3 weeks of JQ1 (50 mg/kg QD)
revealed a significant, 4.5-fold reduction in sperm motility
(16.0% for the JQ1-treated versus 72.4% for the control; Figure 3E). Following 6 weeks of daily JQ1, only 5% of the sperm
demonstrated progressive motility compared to 85% of sperm
from controls (Figure S1). Thus, daily exposure to JQ1 quantitatively reduced sperm number and motility.
Recently, the tolerability of twice-daily administration of JQ1
was reported in a confirmatory study of JQ1 in hematologic
malignancies (Mertz et al., 2011). Pharmacokinetic study of
twice-daily (BID) JQ1 (50 mg/kg) confirmed excellent penetration
of the blood:testis barrier and demonstrated a marked increase
in drug exposure in the testis (AUC0–24hr = 96,640 hr*ng/ml; Figure 3F and Table S4), accompanied by apparent partitioning into
this compartment (AUCtestis/AUCplasma = 236%). With BID injections of JQ1 (JQ1 50 mg/kg), adult males treated for 3 weeks
(9–12 weeks) showed reduction in testis weight to 63.3% of
controls (Figure 3G). Paralleling the reduction in testis weights,
BID treatment resulted in reduction in sperm in the cauda epididymis to 35.6% of the control (Figure 3H), a dramatic 5.8-fold
reduction in sperm motility (11.2% for JQ1-treated versus
64.5% for controls; Figure 3I), firmly establishing the tolerability
and antispermatogenic effect of BID JQ1 in mice. Altogether,
Cell 150, 673–684, August 17, 2012 ª2012 Elsevier Inc. 675
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Figure 2. Molecular Recognition of BRDT by JQ1
(A) Crystal structure of the complex of (+)-JQ1 with hBRDT(1). The ligand is shown as a Corey-Pauling-Koltun (CPK) model, and the hydrogen bond formed to the
conserved asparagine (N109) is shown as yellow dots. Main secondary structural elements are labeled.
(B) The acetyl-lysine binding pocket of the N-terminal bromodomain of hBRDT is shown as a semitransparent surface with contact residues labeled and depicted
in stick representation. Carbon atoms of (+)-JQ1 are colored blue to distinguish them from protein residues. N109 is labeled in blue, and a unique N-terminal
residue is shown in red.
(C) The surface structure of the acetyl-lysine recognition pocket of mBrdt(1) is shown in blue, with key residues highlighted in black, N109 highlighted in blue, and
a distinct residue shown in red.
(D and E) Competitive binding of JQ1 to the acetyl-lysine recognition pocket of hBRDT(1) illustrated by structural alignment to an acetylated histone peptide
binding to mBrdt(1) (PDB: 2WP2). (D) Human BRDT(1) is shown as pink ribbons. JQ1 is shown as blue sticks with colored heteroatoms. N109 is highlighted in blue.
The diacetylated histone H4 peptide is shown in yellow with colored heteroatoms. (E) The diacetyl-lysine recognition site on hBRDT is shown as a pink translucent
surface over stick representations of critical binding residues. Key contact residues are highlighted in black. JQ1 is shown as blue sticks with colored heteroatoms. N109 is highlighted in blue text. The diacetylated histone H4 peptide is shown in yellow with colored heteroatoms. (D and E) JQ1 completely occupies the
hydrophobic pocket which engages the diacetylated peptide.
See also Table S2.

these findings are similar to defects observed in mice deficient in
BRDT(1) (Shang et al., 2007).
JQ1 Selectively Targets Male Germ Cells without
Affecting Hormone Levels
Based on the observed inhibition of spermatogenesis, we performed further mechanistic studies of BRDT inhibition. Consistent with the reduction in testis volume, the cross-sectional
area of seminiferous tubules from testes of males treated daily
from 3–6 weeks with JQ1 were 84.9% of controls, males treated
from 6–12 weeks with JQ1 were 56.4%, and males treated from
9–12 weeks with JQ1 BID were 65.0% of controls (Figure 3J).
Histological examination established a JQ1-dependent decrease in the amount and number of tubules that had obvious
and abundant round spermatids and spermatozoa in the lumen
(Figures 4A–4H). This was particularly apparent in stage VII
tubules, in which a marked reduction in round spermatids was
observed in JQ1-treated mice. Of note, mice treated with JQ1
676 Cell 150, 673–684, August 17, 2012 ª2012 Elsevier Inc.

BID for 3 weeks had a 79% reduction in round spermatids in
stage VII tubules (112.7 ± 7.4 [controls] versus 23.9 ± 3.6 [JQ1treated]; p < 0.0001). Analysis of epididymides of JQ1-treated
males also showed a similar finding in which fewer sperm were
observed in the epididymal lumen compared to their abundance
in controls (Figure S1). Detailed microscopic analysis of the
testes of mice treated with JQ1 revealed seminiferous tubule
degeneration, sloughing of germ cells, and multinucleated symplasts (Figures 4F and 4H; black arrows), findings also described
in cyclin A1 (Ccna1) knockout mice, which are infertile due to
a spermatocyte block (Liu et al., 1998). Thus, JQ1 treatment
causes a block in spermatogenesis and a resultant reduction in
testicular production of spermatozoa.
Because absence of glycoprotein hormone and abrogation of
androgen signaling pathways cause male infertility (Matzuk and
Lamb, 2008), we measured the serum levels of folliclestimulating hormone (FSH), luteinizing hormone (LH), and testosterone after treatment with JQ1. Differences in the levels of FSH,
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LH, and testosterone were not statistically significant between
control and JQ1-treated males (Figures 3K–3M). Likewise,
weights of the seminal vesicles, a major androgen-responsive
tissue, were similar (Figure S1). These results are consistent
with the presence of histologically normal testosteroneproducing Leydig cells in JQ1-treated males (Figures 4A and
4B; red arrows). Thus, JQ1 effects are specific to germ cells
and do not alter hormone-dependent processes.
Molecular Analysis of the Germ Cell Defects
in JQ1-Treated Testes
To molecularly define the consequences of BRDT inhibition by
JQ1, we performed genome-wide expression analysis of males

0
VEH JQ1

(A) Pharmacokinetic analysis of JQ1 in plasma
(black lines) and testis (red lines) following a single
administration of JQ1 (50 mg/kg IP) to male mice.
Data represent the mean ± SD.
(B) Gross analysis of testes from 9-week-old mice
that received control or JQ1 (50 mg/kg daily) for
3 weeks.
(C) Testis weights from mice treated with control or
JQ1 (50 mg/kg QD) for 3–6 weeks, 6–9 weeks, or
6–12 weeks of age. Data represent the mean ±
SEM and are annotated with P values obtained
from a two-tailed t test (*p < 0.05).
(D) Graphical representation of sperm counts
obtained from the entire epididymides of males
treated with JQ1 or control from 6–9 weeks of
age or the tail of the epididymis of males treated
from 6–12 weeks of age with vehicle or JQ1
(50 mg/kg QD). Data represent the mean ± SEM
(*p < 0.05).
(E) Motility of mature sperm obtained from the
cauda epididymis of adult males treated with JQ1
(50 mg/kg daily) from 6–12 weeks of age. Data
represent the mean ± SEM (*p < 0.0001).
(F) Pharmacokinetic analysis of JQ1 in plasma
(black lines) and testis (red lines) following twicedaily (BID) administration of JQ1 (50 mg/kg IP) to
male mice. Data represent the mean ± SD.
(G) Testis weights (mg) from mice treated with
control or JQ1 (50 mg/kg BID) from 9–12 weeks of
age. Data represent the mean ± SEM (*p < 0.05).
(H) Sperm counts obtained from the cauda epididymis of males treated from 9–12 weeks of age
with vehicle or JQ1 (50 mg/kg BID). Data represent
the mean ± SEM (*p < 0.05).
(I) Motility of mature sperm obtained from the
cauda epididymis of adult males treated with JQ1
(50 mg/kg BID) or vehicle from 9–12 weeks. Data
represent the mean ± SEM (*p < 0.001).
(J) Cross-sectional area of seminiferous tubules
from JQ1-treated mice (50 mg/kg QD for
3–6 weeks or 6–12 weeks, or 50 mg/kg BID for
9–12 weeks, as shown) or control (*p < 0.05).
(K, L, and M) Male mice treated with JQ1 or vehicle
from 6–12 weeks exhibit statistically similar serum
levels of (K) testosterone, (L) luteinizing hormone
(LH), and (M) follicle-stimulating hormone (FSH).
See also Figure S1 and Tables S3 and S4.

treated with 50 mg/kg JQ1 daily for 6 weeks (6–12 weeks of age).
Hierarchical clustering separated samples by treatment assignment and identified 1,685 unique genes enriched or upregulated
and 675 unique genes depleted or downregulated (2-fold or
greater; Q value < 0.05) with JQ1 exposure (Figure 5A). The broad
transcriptional events observed—more than an order of magnitude greater than prior studies of JQ1 (Delmore et al., 2011) —suggested a pronounced effect on multistage differentiation more
than selective effects on discrete transcriptional programs.
Multiple germ-cell-expressed genes were suppressed upon treatment with JQ1, including Ccna1 (expressed in pachytene spermatocytes), Msy2 (pachytene spermatocytes and postmeiotic
germ cells), polo-like kinase 1 (Plk1; diplotene and diakinesis
Cell 150, 673–684, August 17, 2012 ª2012 Elsevier Inc. 677

Figure 4. Histological Analysis of the Antispermatogenic Effects of JQ1
(A and B) Histology of stage VII seminiferous
tubules of testes of 6-week-old mice treated with
(A) vehicle control or (B) JQ1 (50 mg/kg QD) from
3–6 weeks of age (403 magnification). Red arrows
indicate intertubular Leydig cell islands.
(C and D) Histology of stage VII seminiferous
tubules of 12-week-old mice treated with (C)
control or (D) JQ1 (50 mg/kg QD) from 6–12 weeks.
A large mass of sloughed epithelium is observed in
the lumen of the tubule in (D).
(E–H) Histological analysis of testis tubules from
12-week-old mice treated with vehicle control
(E, 403; G, 1003) or JQ1 (50 mg/kg BID) (F, 403;
H, 1003) for 3 weeks. Whereas the stage VII
tubules of the control show an abundance of round
spermatids (red arrowheads, G), only a few normal
appearing round spermatids are evident in (H) after
JQ1 treatment. Abnormal spermatids with large
nuclei and abundant cytoplasm (blue arrowheads)
and symplasts (black arrows in F and H) are also
observed.

stage spermatocytes, secondary spermatocytes, and round spermatids), aurora kinase C (Aurkc; chromocenter clusters in diplotene spermatocytes), and A-kinase anchoring protein 4 (Akap4;
postmeiotic germ cells). These results are significant because
knockout mice lacking cyclin A1 have a spermatocyte block (Liu
et al., 1998); Msy2 knockout mice are sterile due to postmeiotic
germ cell block and multinucleated spermatids (Yang et al.,
2005); absence of AKAP4 prevents progressive motility (Miki
et al., 2002); humans with aurora kinase C mutations demonstrate
polyploid nuclei secondary to meiosis I arrest (Dieterich et al.,
2007); and the mammalian PLK1 protein, similar to fruit fly polo
kinase, is believed to function in the completion of meiotic division.
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To determine the stages of spermatogenesis at which JQ1 functions, we then
queried these data with functionally
defined gene sets reflecting early (pachytene spermatocyte) or late (spermatid)
transcriptional signatures (Schultz et al.,
2003) and observed coordinate depletion
(normalized enrichment score [NES] =
2.5 to 2.1; p < 0.001) in three independent modules by gene set enrichment
analysis (GSEA).
Our expression profiling results were
confirmed and extended by gene-specific
RT-PCR (Figure 5D and Table S6). Genes
expressed early in spermatogenesis such
as Plzf, a spermatogonial marker, and
Stra8, expressed in differentiating spermatogonia and preleptotene spermatocytes, are 2.0- and 1.3-fold enriched,
respectively, in testes of JQ1-treated
mice compared to controls. In addition to
Ccna1, Msy2, Plk1, Aurkc, and Akap4,
other key genes expressed during meiosis
or spermiogenesis, including Brdt (mid- to late-spermatocytes),
Papolb (step 1–7 round spermatids), Klf17 (step 4–7 spermatids),
and Prm1 (step 7–16 spermatids), are 2.1- to 7.3-fold lower in
testes of mice treated with JQ1 versus control. Unlike the Brdt
mutant mouse (Shang et al., 2007), in which pachytene spermatocyte-expressed gene Hist1h1t is upregulated, JQ1 treatment
leads to a 2.6-fold downregulation of this gene, in line with
suppression of Brdt, Ccna1, Msy2, and Plk1. This difference is
likely secondary to enhanced blockade of BRDT function by
JQ1 in spermatocytes compared to the Brdt hypomorphic mouse.
To further characterize the consequences of these molecular
changes, we performed histological analysis of zona pellucida
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Figure 5. Selective Depletion of Germ Cell Transcripts by JQ1
(A) Heatmap representation of the top 25 down- and upregulated genes (Q <
0.05) following treatment of male mice with JQ1 (50 mg/kg from 6–12 weeks).
Plk1 and Ccna1 (bold) are downregulated by JQ1 exposure.
(B) GSEA of three spermatogenesis gene clusters (Schultz et al., 2003) in the
testicular transcriptional profile of JQ1-treated males.
(C) GSEA of a canonical MYC-dependent gene set (Zeller et al., 2003) in the
testicular transcriptional profile of JQ1-treated male mice.
(D) Quantitative RT-PCR analysis of males treated from 6–12 weeks of age with
JQ1 or vehicle. The mouse genes are Plzf (promyelocytic leukemia zinc-finger
or Zbtb16), Stra8 (stimulated by retinoic acid gene 8), Brdt (bromodomain,
testis-specific), Ccna1, Hist1h1t (histone cluster 1, histone 1, testis-specific),
Msy2 (Y box protein 2 or Ybx2), Papolb (poly (A) polymerase b or Tpap), Klf17
(Kruppel-like factor 17 or Zfp393), and Prm1 (protamine 1). Data represent the
mean ± SEM and are annotated with p values as obtained from a two-tailed t
test (*p < 0.05; **p < 0.001; the p value for Prm1 is 0.06).
See also Tables S5 and S6.

binding protein 1 (ZPBP1) and transition protein 2 (TNP2). ZPBP1
is an acrosomal matrix protein first detected in round spermatids
as the acrosome forms (Lin et al., 2007), and TNP2 is expressed
in the nuclei of step 10–15 spermatids during histone-toprotamine transition (Zhao et al., 2004). Consistent with transcriptional analysis, JQ1 treatment for 3 or 6 weeks reduced
the number of round spermatids, elongating spermatids, elongated spermatids, and spermatozoa that are positive for
ZPBP1 (Figures 6A–6D and S2) and TNP2 (Figures 6E and 6F
and S2). Depending on the severity of the cellular loss in any
specific tubule, JQ1 treatment caused variable losses of spermatocytes positive for GASZ (Figure S2), a piRNA pathway
protein expressed in pachytene spermatocytes in adults (Ma
et al., 2009). The significant effect of JQ1 on the seminiferous
tubule compartment confirms the transfer of JQ1 across the
blood:testis boundary to alter spermatogenesis.
The Bradner laboratory has demonstrated a pronounced antimitotic effect of JQ1 on dividing cancer cells (Delmore et al.,
2011; Filippakopoulos et al., 2010). In BRD4-dependent cancers,
the antitumor efficacy of JQ1 is associated with G1 cell-cycle
arrest. Toxicity to proliferative compartments such as bone
marrow or bowel has not been observed. To firmly exclude
a BRD4-mediated, nonspecific antimitotic effect of JQ1 in testes,
we stained testis sections for phosphorylated serine 10 of histone
H3 (pH3Ser10), which accumulates in the nuclei of mitotic
spermatogonia during chromatin condensation. Changes in
pH3Ser10 are not seen, supporting a selective effect of JQ1 on
spermatocytes and during spermiogenesis (Figures 6G and
6H). Further supporting a nontoxic effect of JQ1 on spermatogonia, quantitative microscopic analysis failed to identify any
statistically significant decrease in the abundance of cyclinD1-positive nuclei or any increase in TUNEL-positive cells
(Figure S3).
In translational models of solid and hematologic malignancies,
the cancer-specific antiproliferative activity of JQ1 has been
mechanistically linked to addiction to the BRD4 proto-oncogene
(Filippakopoulos et al., 2010) or oncogenic MYC (a BRD4 target
gene) (Delmore et al., 2011; Zuber et al., 2011). In cancer models,
BET bromodomain inhibition by JQ1 results in the coordinated
downregulation of the Myc transcriptional program (Delmore
et al., 2011; Zuber et al., 2011). Though Myc is expressed in
type B spermatogonia and early prophase spermatocytes
(Wolfes et al., 1989), JQ1 exposure did not suppress the expression of MYC target genes, as assessed by GSEA using the functionally defined MYC signature validated by Dang and
colleagues (Figure 5C) (Zeller et al., 2003). Paradoxically, MYCdependent genes trended toward increased expression (NES =
1.8; p < 0.001), possibly due to enrichment of spermatogonial
RNA amidst depletion of spermatids and spermatozoa.
Together, these orthogonal measurements of spermatogonial
transcription, appearance, and function rule out a nonspecific
antiproliferative effect of JQ1 on BET bromodomains within
mitotic germ cells.
BRDT Inhibition Confers a Reversible Contraceptive
Effect in Males
To determine the effects of alternative JQ1 treatment regimens
on the fertility of male mice, JQ1 (50 mg/kg/day) and vehicle
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Figure 6. Histological Evidence of Antispermatogenic Effects of JQ1
(A and B) Immunohistochemical analysis (403) of
ZPBP1 in stage VII seminiferous tubules of males
treated daily from 6–12 weeks with (A) vehicle or
(B) JQ1.
(C and D) Immunofluorescence analysis (203) of
ZPBP1 in testis tubules of males treated BID from
9–12 weeks with (C) vehicle or (D) JQ1.
(E and F) Immunohistochemical analysis (403) of
TNP2 in testis tubules of males treated BID from
9–12 weeks with (E) vehicle or (F) JQ1.
(G and H) Exposure to JQ1 has no effect on mitotic
progression or meiotic chromatin condensation,
as determined by histone 3 phosphoserine 10
(pH3Ser10) staining of testis tubules of males
treated daily from 6–12 weeks with (G) vehicle or
(H) JQ1.
See also Figures S2 and S3.

control were each delivered to 10 male mice for 6 weeks. To
ensure that JQ1 and vehicle were having proper effects, three
males from each group were sacrificed and were shown to
have reduced testis size (control: 107.4 ± 8.8; JQ1: 62.8 ±
7.5 mg; p < 0.05), sperm counts (control: 12.3 ± 0.6 3 106;
JQ1: 3.8 ± 0.3 3 106; p < 0.0001), and sperm motility (control:
72.4 ± 2.5%; JQ1: 16.0 ± 0.1%; p < 0.0001). After this pretreatment period, the remaining seven JQ1-treated and seven control
males were mated continuously to two adult females per male
while continuing to receive JQ1 or vehicle. After the first month
of breeding, the seven control males had sired 14 litters of
offspring. However, only four of the seven JQ1-treated males
680 Cell 150, 673–684, August 17, 2012 ª2012 Elsevier Inc.

sired offspring (only six litters of offspring
and a reduced number of pups). For the
three JQ1-treated males that had not yet
sired offspring, these mice demonstrated
normal mating behavior as evident by the
presence of copulation plugs. Thus, even
at a low dose of JQ1, there is a partial
contraceptive effect.
As the mice appeared to be healthy at
50 mg/kg/day of JQ1, we escalated the
dosage of JQ1 in the second mating
month to 75 mg/kg/day. The male mice
appeared to fall into two groups: those
that show a contraceptive effect with
50 mg/kg/day followed by 75 mg/kg/day
(Figure 7A) and those that still produced
at least one litter under this lower-dose
regimen (Figure 7B). For the three mice
that were most responsive to the lowdose regimen, only one was able to sire
a litter of two offspring (born on the first
day of month 2). For the latter group, the
four males that sired offspring were
treated in mating month 3 with 50 mg/kg
twice per day. These males were not
observed to sire any offspring in month
3 (Figure 7B). Thus, depending on individual variability of each
of the males, total daily dosages between 50 and 100 mg/kg
can produce a complete contraceptive effect in male mice.
To assess the reversibility of the JQ1-induced contraceptive
effect, we examined whether fertility returned after JQ1 treatment was halted. Among the three infertile mice treated with
the low-dose regimen, infertility remained complete at 1 month
of recovery (mating month 3), indicating a durable effect of
JQ1 on spermatogenesis. However, in mating month 4, all three
males sired offspring with a statistically similar number of pups
per female as observed for the controls (Figure 7A). The average
days to effective copulation was estimated to be 31.7 ± 6.0 days
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(range: 26–38 days) based on the birth of the first litters after
treatment was stopped and the 19 day gestation period of
mice. After a total mating period of 7 months (i.e., 4 months after
halting the low-dose regimen), testis volume, seminiferous
tubule area, testis histology, sperm motility, and sperm counts
were statistically similar to the control group (Figures 7C–7E
and S4), consistent with fully recovered fertility. Thus, mice
treated with JQ1 at 50 mg/kg/day and then 75 mg/kg/day
recover fertility within 6 weeks of withholding the drug and
show no long-term effects of JQ1 treatment. For the mice that
required escalation to the high-dose regimen (50 mg/kg BID),
JQ1 was halted after the first month of this treatment (i.e., treatment month 3). In months 4 and 5, these males failed to sire
offspring (Figure 7B). However, all JQ1-treated males sired
offspring in month 6 and sired similar litter sizes as controls in
months 6–8. The average days to effective copulation for this
cohort was estimated to be 65.7 ± 7.7 days (range:
58–81 days). Thus, longer JQ1 treatment and/or the increased
dosage of JQ1 resulted in an extended (1 month) period of
infertility.
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Figure 7. BRDT Inhibition with JQ1 Causes
a Reversible Contraceptive Effect in Male
Mice

(A) Adult males were pretreated for 6 weeks with
vehicle control (n = 7) or JQ1 (50 mg/kg QD; n = 3)
and then caged continuously with two females
each while continuing 50 mpk QD for month 1 and
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(C–E) Graphical representation of (C) testis mass
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low-dose regimen shown in (A) (data represent
mean ± SEM; NS, not significant).
(F–H) Graphical representation of (F) testis mass,
(G) sperm count, and (H) sperm motility of adult
control males (n = 4) and JQ1-treated males after
3 weeks of 50 mg/kg BID treatment (n = 2), as well
as following 10 days (n = 2), 30 days (n = 2), and
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regimen (data represent mean ± SEM; *p < 0.05).
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To more precisely determine the integrity and function of the
testes and spermatozoa following withdrawal of JQ1 therapy,
two additional independent experiments were performed. In the
first experiment, JQ1-treated adult male mice were examined at
the end of 6 weeks of treatment (50 mg/kg/day) or after 2 or
4 months following cessation of therapy. After 2 months, the testis
weight and sperm counts and motility were increased, and after
4 months, the weights and sperm parameters approached normal
levels (Figure S4). Histologically, seminiferous tubules of JQ1treated mice are indistinguishable from controls (Figures 7I and
7J). In the second experiment, a cohort of mice was treated
with vehicle or 3 weeks of high-dose JQ1 (50 mg/kg BID). Mice
were sacrificed at 3 weeks of treatment and 10, 30, and 60 days
after JQ1 withdrawal. Males treated with high-dose JQ1 continue
to show defects in testicular parameters 30 days after halting
treatment but exhibit complete recovery of all parameters within
60 days (Figures 7F–7H), consistent with the documented recovery of fertility. Thus, depending on duration and overall dosage of JQ1, testicular and semen parameters normalize within
1–3 months to allow productive copulation and return of fertility.
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Lastly, offspring that were born from JQ1-treated males
showed normal size, activity, and behavior as offspring born
from controls (Figure 7K and data not shown). When offspring
from vehicle and JQ1-treated fathers were allowed to mate
with adult females (2 females/cage) at 6 weeks of age, both
sets of males (n = 6 for each group) displayed normal mating
behavior, sired offspring from each female, and produced statistically similar litter sizes from matings over the first month
(control: 7.73 ± 0.70 pups/litter; JQ1: 7.50 ± 0.34 pups/litter).
At 11 weeks of age, the testis weights (control: 98.7 ± 2.8 mg;
JQ1: 95.8 ± 3.2 mg), sperm counts (control: 11.8 ± 0.3 3 106;
JQ1: 11.2 ± 0.6 3 106), and sperm motility (control: 69.5 ±
1.7%; JQ1: 69.8 ± 1.3%) of the offspring were statistically
similar. Together, these findings indicate that JQ1 did not have
any long-term transgenerational effects on testis physiology or
reproductive capacity.
DISCUSSION
Using a highly potent and selective chemical probe, our studies
provide pharmacologic validation of the amino-terminal bromodomain of BRDT as a target for male contraception. JQ1
emerges as a lead compound for a new class of drugs that can
cross the blood:testis boundary, inhibit bromodomain activity
during spermatogenesis, impair sperm generation and motility,
and produce a reversible contraceptive effect in mammals.
These data support JQ1 as the first contraceptive agent that
selectively and reversibly targets the male germ cell.
Modulation of chromatin structure during spermatogenesis by
an inhibitor of an epigenetic reader protein, such as BRDT, raises
concern for epigenetic developmental abnormalities in progeny
born to animals on treatment or following cessation. To date,
we have not identified any anomalous phenotypes in offspring
during or following exposure to JQ1. Targeting the male germ
cell might raise concern for irreversible toxicity and resultant
infertility. We have only observed full recovery of fertility in
treated males; testis size, seminiferous tubule diameter, histological appearance, sperm number and motility, and fertility of
JQ1-treated males recover to the levels of controls (Figures 7
and S4). These observations are consistent with the restricted
expression of the BRDT target in pachytene spermatocytes
through round spermatids and with the function of BRDT in these
stages to promote spermatogenesis. Indeed, the phenotype
of mice treated with JQ1 closely resembles the seminal
findings by Wolgemuth and colleagues in the characterization
of BRDT(1) hypomorphic mice (Shang et al., 2007). We cannot
rule out that some of effects of JQ1 are through inhibition of other
members of the BET subfamily that are also expressed in murine
testes (e.g., BRD4 [mRNA expressed in spermatogonia], BRD2
[diplotene spermatocytes], and BRD3 [round spermatids])
(Shang et al., 2004). However, the mitotic status of spermatogonia is unaltered in the JQ1-treated males, and we do not
observe end-organ toxicity in testis or other tissues in mice,
such as the gastrointestinal mucosa, suggestive of a generalized
antimitotic effect, as might be expected with inhibition of BRD4
(Dey et al., 2003). Unequivocally, JQ1 is a BET family inhibitor
that exerts its contraceptive effect on the male germline during
the peak of expression of BRDT.
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This chemical genetic study of bromodomain inhibition for
male contraception provides pharmacologic target validation,
encourages further drug development efforts, and offers insights
guiding and enabling pharmaceutical BRDT inhibitor development. As this index study closely examines effects on human
and murine BRDT, further study of additional species may be
relevant for drug development. Toward this objective, we have
completed preliminary studies of JQ1 in rats in which we have
observed excellent pharmacologic exposure to JQ1 by i.p. injection (Figure S5A and Table S7) and have identified a tolerated
dose (10 mg/kg BID), which is effective in reducing testis
mass, sperm count, and motility (Figures S5B–S5D), accompanied by comparable histological evidence of impaired spermiogenesis (Figure S5E). For a chemical probe intended for
laboratory research, JQ1 has excellent drug-like properties yet
possesses a short terminal elimination half-life. Pharmacokinetic
studies performed herein demonstrate that excellent drug exposure can be accomplished with twice-daily administration.
The observed complete contraceptive effect of JQ1 when given
twice daily suggests that more continuous inhibition of BRDTdependent effects on spermatogenesis may be required for clinical translation of this research.
We are currently creating and testing the effects of JQ1 derivatives possessing selectivity for BRDT to extend the favorable
therapeutic window of BRDT inhibition for male contraception.
Recently described tool compounds of BET bromodomains
provide divergent putative scaffolds for lead optimization (Chung
et al., 2011; Dawson et al., 2011; Nicodeme et al., 2010).
Compounds that demonstrate higher affinity and specificity for
BRDT would be expected to reduce any possible long-term,
adverse effects of a pan-BET bromodomain inhibitor. Structural
and sequence comparisons of BRDT(1) and BRD4(1) reveal
differences in surface residues that may be explored to develop
further isoform-selective BET inhibitors. Because human and
mouse BRDT proteins are highly conserved and have nearly
identical bromodomain pockets based on our structural predictions, we envision that our discoveries can be completely translated to men, providing a novel and efficacious strategy for
a male contraceptive.
EXPERIMENTAL PROCEDURES
(+)-JQ1
The direct-acting, small-molecule bromodomain inhibitor was prepared as
described (Filippakopoulos et al., 2010).
Protein Cloning
cDNA-encoding BRDT (human: NCBI accession number AAB87862.1,
obtained from FivePrime; murine: NCBI accession number EDL20168.1,
obtained from Dr. Saadi Khochbin) was used as template to PCR amplify the
N-terminal bromodomain regions of human and murine BRDT. PCR products
were isolated and subcloned into a pMCSG7-derived expression vector
(pNIC28-Bsa4), using ligation-independent cloning. The constructs (hBRDT(1)
21–137, hBRDT(2) 257–382, mBRDT(1) 23–133, and mBRDT(2) 257–383) were
transformed into competent Mach1 cells (Invitrogen, UK) to yield the final
plasmid.
BRDT Proximity Assay
AlphaScreen assays were performed on an Envision 2104 instrument with
minor modifications from the manufacturer’s protocol (PerkinElmer, USA).

Isothermal Titration Calorimetry
Isothermal titration calorimetry (ITC) was carried out on a VP-ITC titration
microcalorimeter from MicroCal, LLC (Northampton, MA). Dissociation
constants and thermodynamic parameters are listed in Figure 1.
Crystallization of BRDT and (+)-JQ1
BRDT(1) crystallizations were carried out using the sitting drop vapor diffusion method at 4 C using a mosquito crystallization robot (TTP Labtech,
Royston, UK). Data collection and refinement statistics can be found in
Table S2. The model and structure factors have been deposited with PDB
accession code: 4FLP.
Mouse Contraceptive Studies
(+)-JQ1 was dissolved in DMSO at 50 mg/ml, 75 mg/ml, or 100 mg/ml
and then diluted 1:10 in 10% (2-Hydroxypropyl)-b-cyclodextrin (SigmaAldrich) or 20% Captisol (CYDEX, Lenexa, KS). The mixture was injected
i.p. into male mice at 1% of the body weight (50 mg/kg or 75 mg/kg) or
0.5% of the body weight for the 50 mg/kg BID injections. The control
was DMSO dissolved 1:10 in 10% (2-Hydroxypropyl)-b-cyclodextrin or
20% Captisol and injected similarly. Juvenile or adult C57BL6/J/129S5
hybrid mice for these studies were weighed daily before injections and fed
ad libitum.
For mating studies, males were pretreated for 6 weeks with vehicle or
JQ1 and caged continuously with two females each while continuing 50 mpk
QD for month 1 and escalating to 75 mg QD for month 2. The JQ1-treated
males that were responsive to this ‘‘low-dose’’ treatment regimen were
allowed to recover untreated while continuing to breed to 2 females per
cage through 7 months of continuous breeding. Males that continued to sire
offspring in month 2 were treated in month 3 of breeding with 50 mg/kg BID
(‘‘high-dose’’ regimen), and JQ1 treatment was stopped for these males and
controls while continuing to breed to 2 females per cage through 8 months
of continuous breeding. Cages were checked daily, and offspring born per
each female were recorded.
For the recovery studies, males were sacrificed post-JQ1 and control
treatment, and testis and sperm parameters were determined. These
studies were approved by the Administrative Committee on Laboratory
Animal Care at Baylor College of Medicine, and all experiments were conducted in accordance with the NIH guide for the Care and Use of Laboratory
Animals.
Histology and Measurement of Testis Seminiferous Tubule Area
Testes and epididymides were fixed in Bouin’s solution and processed for
sectioning. Digital images of cross-sections were captured, and 25 tubules
were randomly selected for each sample. Seminiferous tubule area was
determined using NIH Image J software. The mean ± SEM of the tubule area
for each treatment group was calculated, and comparisons between control
and JQ1 treatment groups were made using a t test.
Epididymal Sperm Counts and Motility
Counts were performed on spermatozoa isolated from the entire epididymis or
from the caudal epididymis of mice as described (Roy et al., 2007). In brief,
epididymides were dissected and placed in prewarmed M2 medium, minced,
and incubated at 37 C for 30 min in a CO2 incubator prior to counting and
analysis of sperm motility.
Gene Expression Analyses
Total RNA from mouse testes was isolated using TRIzol reagent (Invitrogen)
and processed for Illumina gene expression analysis or QPCR.
ACCESSION NUMBERS
Atomic coordinates and structure factors for the reported crystal structure of
BRDT(1) with JQ1 have been deposited with the Protein Data Bank under
accession code 4FLP. Gene expression data were deposited in the GEO database with accession GSE37894.

SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, two data files, and seven tables and can be found with this article
online at http://dx.doi.org/10.1016/j.cell.2012.06.045.
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